Gilead Sciences, Inc. vs Iris Energy Limited — how do they compare? Gilead Sciences, Inc. trades at $135.78 (market cap $168.35B), while Iris Energy Limited trades at $42.75 (market cap $14.20B). The key difference: Gilead Sciences, Inc. is far larger — about 11.9× Iris Energy Limited's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| GILD | IREN | |
|---|---|---|
Market Cap | $168.35B | $14.20B |
Sector | Health | Energy |
52-Week High | $155.80 | $76.41 |
52-Week Low | $110.56 | $17.73 |
Enterprise Value | $191.42B | $15.95B |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
IREN trades at $43.24, up 11.62% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 revenue of $501.02M and net income of $86.94M, but missed EPS estimates for three consecutive quarters. Recent news highlights a $2.8B AI contract surge and a raised revenue target above $4B, driving investor optimism despite high valuation ratios like a P/E of 51.6.
Outlook is mixed: strong AI contract growth and analyst consensus price target of $84.43 suggest upside, but execution risks, high valuations, and consistent earnings misses pose challenges. Stock sentiment is buoyed by institutional interest, including a new position by California State Teachers Retirement System in Q2 2026.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →